Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.58 |
| ▸ | ACACB | O00763 | 3/20 | 0.51 |
| ▸ | ACACA | Q13085 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9111530 | 1.00 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACAMAOA | |
| SCHEMBL15641638 | 0.85 | MTNR1A (0.59) | MTNR1AMTNR1BACACBACACAPTGS1 | |
| SCHEMBL9114739 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACAMAOA | |
| SCHEMBL21749916 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL21749917 | 0.84 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9112634 | 0.83 | MTNR1A (0.56) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL9109525 | 0.81 | MTNR1A (0.55) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18027261 | 0.81 | MTNR1A (0.48) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL18290032 | 0.81 | MTNR1A (0.48) | MTNR1AMTNR1BACACBACACA | |
| SCHEMBL2551008 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BACACBACACAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180127378-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-10 | — | — | US | disclosed |
| EP-3302471-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | Eisai R&D Management Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9796683-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-10-24 | — | — | US | disclosed |
| WO-2016196337-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196346-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-08 | — | — | WO | disclosed |
| US-20160347717-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | BRCA1, ESR2, ESR1 | MTNR1A 3975/4885MTNR1B 3782/4885ACACB 1737/4885 |
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | MTNR1A 995/4885MTNR1B 750/4885ACACB 28/4885 |
| US-20160347717-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | MTNR1A 3975/4885MTNR1B 3782/4885ACACB 1737/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | MTNR1A 995/4885MTNR1B 750/4885ACACB 28/4885 |
| US-20180127378-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | MTNR1A 3975/4885MTNR1B 3782/4885ACACB 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.